Cardinal Capital Management Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Cardinal Capital Management purchased a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 44,483 shares of the medical device company's stock, valued at approximately $3,459,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Jennison Associates LLC increased its position in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Congress Asset Management Co. increased its position in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company's stock valued at $76,659,000 after purchasing an additional 739,000 shares during the last quarter. Finally, Intech Investment Management LLC grew its position in DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company's stock worth $25,967,000 after acquiring an additional 369,587 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DXCM shares. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and raised their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Oppenheimer reduced their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Leerink Partners reduced their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.06.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $3,309,794 in the last quarter. 0.30% of the stock is owned by company insiders.

DexCom Stock Down 0.6 %

Shares of DXCM traded down $0.56 on Friday, reaching $88.78. The stock had a trading volume of 3,729,437 shares, compared to its average volume of 3,632,823. The firm has a market capitalization of $34.69 billion, a price-to-earnings ratio of 62.08, a price-to-earnings-growth ratio of 2.31 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a 50-day simple moving average of $83.26 and a 200-day simple moving average of $75.94. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.